My #1 Pre IPO Trade for 2025 – NAME and TICKER

One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...

Prabhavathi Fernandes net worth and biography

Prabhavathi Fernandes Biography and Net Worth

Director of Ocugen

Dr. Prabhavathi Fernandes, Ph.D., has more than 35 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving Bristol- Myers Squibb, she has founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies, including Cempra, Inc., DarPharma, Ricerca and Small Molecule Therapeutics. Dr. Fernandes is the Chairperson of both the National Biodefense Science Board (NBSB) and the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership, a DNDi/WHO initiative. She has also served as an advisor to the World Health Organization. She currently serves on the Boards of OpGen and Aelin Therapeutics. She has authored over 250 publications and several reviews, book chapters and served as an editor for books. Dr. Fernandes obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, received her Ph.D. in Microbiology from Thomas Jefferson University, Philadelphia.

What is Prabhavathi Fernandes' net worth?: The estimated net worth of Prabhavathi Fernandes is at least $17,598.75 as of May 25th, 2021. Dr. Fernandes owns 19,500 shares of Ocugen stock worth more than $17,599 as of November 21st. This net worth estimate does not reflect any other investments that Dr. Fernandes may own. Learn More about Prabhavathi Fernandes' net worth.
How do I contact Prabhavathi Fernandes?: The corporate mailing address for Dr. Fernandes and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Prabhavathi Fernandes' contact information.
Has Prabhavathi Fernandes been buying or selling shares of Ocugen?: Prabhavathi Fernandes has not been actively trading shares of Ocugen over the course of the past ninety days. Most recently, Prabhavathi Fernandes sold 33,500 shares of the business's stock in a transaction on Tuesday, May 25th. The shares were sold at an average price of $8.20, for a transaction totalling $274,700.00. Following the completion of the sale, the director now directly owns 19,500 shares of the company's stock, valued at $159,900. Learn More on Prabhavathi Fernandes' trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Prabhavathi Fernandes Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/25/2021	Sell	33,500	$8.20	$274,700.00	19,500

Prabhavathi Fernandes Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.90

$0.89

$0.92

50 Day Range

MA: $0.99

$0.87

$1.21

2 Week Range

Now: $0.90

$0.36

$2.11

Volume

216,821 shs

Average Volume

6,075,705 shs

Market Capitalization

$262.92 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.75